Publicacións en colaboración con investigadores/as de Universidad de Salamanca (11)

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2018

  1. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

    Blood cancer journal, Vol. 8, Núm. 12, pp. 117

2016

  1. Effect of mTORC1/mTORC2 inhibition on T cell function: Potential role in graft-versus-host disease control

    British Journal of Haematology, Vol. 173, Núm. 5, pp. 754-768

  2. Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development

    Journal of Hematology and Oncology, Vol. 9, Núm. 1

2009

  1. Prolonged idiotypic vaccination against follicular lymphoma

    Leukemia and Lymphoma, Vol. 50, Núm. 1, pp. 47-53

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

  2. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation

    Leukemia and Lymphoma, Vol. 47, Núm. 1, pp. 29-37

2004

  1. Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis

    Clinical Cancer Research, Vol. 10, Núm. 2, pp. 751-761